- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04493034
Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
A Randomized Controlled Trial to Assess the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A cancer diagnosis is often associated with adverse psychosocial effects, including: increased stress and anxiety, fatigue and sleep disturbance, impaired memory and cognition, and poor quality of life. Chemotherapy can cause a cognitive decline in up to 75% of patients; an impairment that oftentimes persists beyond completion of the regimen. This is known as "chemobrain". Integrative therapies are actively being investigated to help improve psychological wellbeing among cancer patients and survivors.
The current standard at this institution is to inform patients of different complementary services that are available, including art therapy, music therapy or acupuncture, but not require patients to use them.
Participants in this study will be randomized to one of three arms 1) Art therapy program, 2) Music therapy program, or 3) Standard of care (SOC). In-person and at-home therapy sessions will be scheduled in alternating, weekly sessions, to allow one week of self-reflection and remote therapy between in-person sessions. Each participant will be asked to attend two in-person therapy sessions per month (total of 6).
The primary objective of this study is to determine the efficacy of a 3-month, therapist-led art or music therapy program to improve quality of life in breast cancer patients currently receiving therapy and in cancer survivors.
Secondary objectives of this study are:
To determine the effect of these programs on patient cognition in this population.
To determine the effect of these programs symptoms of anxiety and depression in this population.
To assess whether the effect of these programs is sustained at a 3-month follow-up.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zeina Nahleh, MD
- Phone Number: +1 954-659-5840
- Email: NAHLEHZ@ccf.org
Study Locations
-
-
Florida
-
Weston, Florida, United States, 33331
- Recruiting
- Cleveland Clinic Florida Weston, Case Comprehensive Cancer Center
-
Contact:
- Zeina Nahleh, MD
- Phone Number: 954-659-5840
- Email: NAHLEHZ@ccf.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Breast cancer diagnosis (stage 0-III)
- Treated at Cleveland Clinic by medical oncologist, radiation oncologist, and/or breast surgeon Patients currently undergoing treatment or have completed active treatment (surgery, radiation or chemotherapy) within past 5 years.
- Able and willing to participate in art or music therapy programs at Maroone Cancer Center
- Subjects must have the ability to understand and the willingness to sign a written informed consent document
- Ability to read and write in English
- Performance status 0 or 1 as per ECOG scale
Exclusion Criteria:
- No prior history of breast cancer
- History of metastatic disease (Stage IV)
- Not being followed by medical oncologist, radiation oncologist, and/or breast surgeon at Cleveland Clinic
- Unable or unwilling to participate in art or music therapy program at Maroone Cancer Center
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Art Therapy
Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
|
The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:
Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health. |
Experimental: Music Therapy
Weekly sessions, alternating: in-person sessions (6 over 3 months), home assignments (6 over 3 months)
|
Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting. For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study. |
No Intervention: Standard Of Care
A list of support services is provided.
No requirement to attend sessions and no home assignments
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy: Breast Cancer (FACT-B) questionnaire scores
Time Frame: Baseline
|
Quality of life (QOL) as measured by Functional Assessment of Cancer Therapy: Breast Cancer (FACT-B) questionnaire.
This is a validated survey, completed by the patient, consisting of 37 items, each scored on a 0-4, Likert scale (0 = "Not at all"; 4= "Very much").
Subscales include: Physical Well-Being (PWB) (score range: 0-28), Social/Family Well-Being (SWB) (score range: 0-28), Emotional Well-Being (EWB) (score range: 0-24), Functional Well-being (FWB) (score range: 0-28), and the additional breast cancer concerns (BCS) (score range: 0-40) all with higher scores indicating better outcomes.
Total scale scores range from 0 to 148 with higher scores indicating better outcomes.
|
Baseline
|
FACT-B questionnaire scores
Time Frame: At 30-days
|
QOL as measured by FACT-B questionnaire scores.
This is a validated survey, completed by the patient, consisting of 37 questions, each scored on a 0-4, Likert scale (0 = "Not at all"; 4= "Very much").
Subscales include: PWB (score range: 0-28), SWB (score range: 0-28), EWB (score range: 0-24), FWB (score range: 0-28), and BCS (score range: 0-40) all with higher scores indicating better outcomes.
Total scale scores range from 0 to 148 with higher scores indicating better outcomes.
|
At 30-days
|
FACT-B questionnaire scores
Time Frame: At 90-days
|
QOL as measured by FACT-B questionnaire scores.
This is a validated survey, completed by the patient, consisting of 37 questions, each scored on a 0-4, Likert scale (0 = "Not at all"; 4= "Very much").
Subscales include: PWB (score range: 0-28), SWB (score range: 0-28), EWB (score range: 0-24), FWB (score range: 0-28), and BCS (score range: 0-40) all with higher scores indicating better outcomes.
Total scale scores range from 0 to 148 with higher scores indicating better outcomes.
|
At 90-days
|
FACT-B questionnaire scores
Time Frame: At 180-days
|
QOL as measured by FACT-B questionnaire scores.
This is a validated survey, completed by the patient, consisting of 37 questions, each scored on a 0-4, Likert scale (0 = "Not at all"; 4= "Very much").
Subscales include: PWB (score range: 0-28), SWB (score range: 0-28), EWB (score range: 0-24), FWB (score range: 0-28), and BCS (score range: 0-40) all with higher scores indicating better outcomes.
Total scale scores range from 0 to 148 with higher scores indicating better outcomes.
|
At 180-days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy - Cognition (FACT-Cog) questionnaire scores
Time Frame: Baseline
|
Cognition as measured by FACT-Cog questionnaire scores. This questionnaire contains 37 items, divided into four subscales: 1) patients' perceived cognitive impairments (score range: 0-72), 2) perceived cognitive abilities (score range: 0-28), 3) Noticeability or comments from others (score range: 0-16), and 4) impact of cognitive changes on QOL (score range: 0-16). Higher scores indicate worse perceived cognitive deficit. FACT-Cog sub-scores are studied on their own and not included in a "total score", as advised by the scoring guidelines |
Baseline
|
FACT-Cog questionnaire scores
Time Frame: At 30-days
|
Cognition as measured by FACT-Cog questionnaire scores. This questionnaire contains 37 items, divided into four subscales: 1) patients' perceived cognitive impairments (score range: 0-72), 2) perceived cognitive abilities (score range: 0-28), 3) Noticeability or comments from others (score range: 0-16), and 4) impact of cognitive changes on QOL (score range: 0-16). Higher scores indicate worse perceived cognitive deficit. FACT-Cog sub-scores are studied on their own and not included in a "total score", as advised by the scoring guidelines |
At 30-days
|
FACT-Cog questionnaire scores
Time Frame: At 90-days
|
Cognition as measured by FACT-Cog questionnaire scores. This questionnaire contains 37 items, divided into four subscales: 1) patients' perceived cognitive impairments (score range: 0-72), 2) perceived cognitive abilities (score range: 0-28), 3) Noticeability or comments from others (score range: 0-16), and 4) impact of cognitive changes on QOL (score range: 0-16). Higher scores indicate worse perceived cognitive deficit. FACT-Cog sub-scores are studied on their own and not included in a "total score", as advised by the scoring guidelines |
At 90-days
|
FACT-Cog questionnaire scores
Time Frame: At 180-days
|
Cognition as measured by FACT-Cog questionnaire scores. This questionnaire contains 37 items, divided into four subscales: 1) patients' perceived cognitive impairments (score range: 0-72), 2) perceived cognitive abilities (score range: 0-28), 3) Noticeability or comments from others (score range: 0-16), and 4) impact of cognitive changes on QOL (score range: 0-16). Higher scores indicate worse perceived cognitive deficit. FACT-Cog sub-scores are studied on their own and not included in a "total score", as advised by the scoring guidelines |
At 180-days
|
Generalized Anxiety Disorder-7 item (GAD-7) scores
Time Frame: Baseline
|
Self-reported anxiety as measured by GAD-7 scores.
Scoring is scaled, as follows: 0 indicates "not at all", 1 indicates "several days", 2 indicates "more than half of the days", and 3 indicates "nearly every day for anxiety frequency".
|
Baseline
|
Generalized Anxiety Disorder-7 item (GAD-7) scores
Time Frame: At 30-days
|
Self-reported anxiety as measured by GAD-7 scores.
Scoring is scaled, as follows: 0 indicates "not at all", 1 indicates "several days", 2 indicates "more than half of the days", and 3 indicates "nearly every day for anxiety frequency".
|
At 30-days
|
Generalized Anxiety Disorder-7 item (GAD-7) scores
Time Frame: At 90-days
|
Self-reported anxiety as measured by GAD-7 scores.
Scoring is scaled, as follows: 0 indicates "not at all", 1 indicates "several days", 2 indicates "more than half of the days", and 3 indicates "nearly every day for anxiety frequency".
|
At 90-days
|
Generalized Anxiety Disorder-7 item (GAD-7) scores
Time Frame: At 180-days
|
Self-reported anxiety as measured by GAD-7 scores.
Scoring is scaled, as follows: 0 indicates "not at all", 1 indicates "several days", 2 indicates "more than half of the days", and 3 indicates "nearly every day for anxiety frequency".
|
At 180-days
|
Patient Health Questionnaire-9 item (PHQ-9) scores
Time Frame: Baseline
|
Self-reported depression as measured by PHQ-9 scores.
A score of 0-4 indicates no depression, a score of 5-9 indicates mild depression, a score of 10-14 indicates moderate depression, and a score of 15 or more indicates severe depression
|
Baseline
|
Patient Health Questionnaire-9 item (PHQ-9) scores
Time Frame: At 30-days
|
Self-reported depression as measured by PHQ-9 scores.
A score of 0-4 indicates no depression, a score of 5-9 indicates mild depression, a score of 10-14 indicates moderate depression, and a score of 15 or more indicates severe depression
|
At 30-days
|
Patient Health Questionnaire-9 item (PHQ-9) scores
Time Frame: At 90-days
|
Self-reported depression as measured by PHQ-9 scores.
A score of 0-4 indicates no depression, a score of 5-9 indicates mild depression, a score of 10-14 indicates moderate depression, and a score of 15 or more indicates severe depression
|
At 90-days
|
Patient Health Questionnaire-9 item (PHQ-9) scores
Time Frame: At 180-days
|
Self-reported depression as measured by PHQ-9 scores.
A score of 0-4 indicates no depression, a score of 5-9 indicates mild depression, a score of 10-14 indicates moderate depression, and a score of 15 or more indicates severe depression
|
At 180-days
|
Attitudes towards art/music scores
Time Frame: Baseline
|
Intervention efficacy as measured by attitudes towards art/music, assessed in 4, 10-point Likert questions with scores ranging from 0 to 40, and higher scores indicating better attitudes. Age, race/ethnicity, marital status, no. of children (if any), occupation, time since diagnosis, current chemotherapy regimen, time since therapy initiated / completed, and attitudes towards art and music will be collected as variables, to assess whether these factors are significant predictors of intervention efficacy. |
Baseline
|
Attitudes towards art/music scores
Time Frame: At 30-days
|
Intervention efficacy as measured by attitudes towards art/music, assessed in 4, 10-point Likert questions with scores ranging from 0 to 40, and higher scores indicating better attitudes.
|
At 30-days
|
Attitudes towards art/music scores
Time Frame: At 90-days
|
Intervention efficacy as measured by attitudes towards art/music, assessed in 4, 10-point Likert questions with scores ranging from 0 to 40, and higher scores indicating better attitudes.
|
At 90-days
|
Attitudes towards art/music scores
Time Frame: At 180-days
|
Intervention efficacy as measured by attitudes towards art/music, assessed in 4, 10-point Likert questions with scores ranging from 0 to 40, and higher scores indicating better attitudes.
|
At 180-days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zeina Nahleh, MD, Cleveland Clinic, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE5120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on Art Therapy
-
Hampton VA Medical CenterTerminatedPost-traumatic Stress Disorder | Stress Disorder, Post-TraumaticUnited States
-
University of DerbyCompletedPerinatal Mental HealthUnited Kingdom
-
Hasan Kalyoncu UniversityIstanbul UniversityRecruiting
-
Walter Reed National Military Medical CenterRecruitingAnger | PTSD | Sleep Disturbance | Posttraumatic Stress Disorder | Combat Stress Disorders | Nightmare | Post-Traumatic Headache | Military Activity | Posttraumatic Stress Disorder, Delayed Onset | Irritable Mood | Combat and Operational Stress Reaction | Military Family | Military OperationsUnited States
-
Walter Reed National Military Medical CenterNational Intrepid Center of ExcellenceRecruitingAnger | PTSD | TBI (Traumatic Brain Injury) | Sleep Disturbance | Headache | Posttraumatic Stress Disorder | Combat Stress Disorders | Eating Disorders | Nightmare | Post-Traumatic Headache | TBI | Military Activity | Posttraumatic Stress Disorder, Delayed Onset | Irritable Mood | Combat and Operational Stress Reaction | Military Family and other conditionsUnited States
-
University Hospital, GhentUniversity GhentCompletedAnorexia Nervosa | Binge-Eating Disorder | Bulimia Nervosa | Eating DisordersBelgium
-
Fundación Pública Andaluza para la Investigación...University of AlcalaCompleted
-
Université de SherbrookeMcGill University; Laval University; Université de Montréal; Concordia University...Completed
-
University of ZurichRecruitingPosttraumatic Stress Disorder | Pancreas Cancer | Depression, Anxiety | Lower Gastrointestinal Neoplasms BenignSwitzerland